XML 63 R44.htm IDEA: XBRL DOCUMENT
v3.20.2

Acquisition, Equity-Method Investment and Licensing Arrangements - BioNTech SE (Details) - Licensing Agreements [Member] - BioNTech SE [Member] - USD ($) $ in Millions |  | 1 Months Ended | 3 Months Ended
--- | --- | --- | ---
Apr. 09, 2020 | Jul. 31, 2020 | Jun. 28, 2020
Business Acquisition [Line Items] |  |  |
Value of shares purchased |  |  | $ 113
Potential future milestone payments | $ 563 |  |
Maximum potential cash payments | $ 748 |  |
Research and development arrangement, percentage of costs to be reimbursed | 50.00% |  |
Research and Development Expense [Member] |  |  |
Business Acquisition [Line Items] |  |  |
Upfront payment for licensing arrangement |  |  | $ 72
Subsequent Event [Member] |  |  |
Business Acquisition [Line Items] |  |  |
Value of shares purchased |  | $ 50 |

X
- Definition Licensing Arrangement, Value Of Shares Purchased + References No definition available. + Details
Name: | pfe_LicensingArrangementValueOfSharesPurchased
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment For Licensing Arrangement + References No definition available. + Details
Name: | pfe_PaymentForLicensingArrangement
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research And Development Arrangement, Contingent Payments, Maximum Exposure1 + References No definition available. + Details
Name: | pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Research And Development Arrangement, Future Milestone Payments, Maximum Exposure + References No definition available. + Details
Name: | pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Research and Development Arrangement, Percentage of Costs to be Reimbursed + References No definition available. + Details
Name: | pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed
Namespace Prefix: | pfe_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pfe_BioNTechSEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |